Pulmonx's revenue forecast for FY24 is closely aligned with analyst estimates, suggesting that the company's financial performance is expected to meet market expectations. This alignment typically indicates a neutral impact on the stock price in the short term, as the forecast does not significantly exceed or fall short of analyst expectations.